Pharmaceutical maker Novartis plans to terminate 500 workers in manufacturing and other “traditional” roles from its Basel, Switzerland headquarters and create 350 high-tech jobs there in shift toward new forms of pharmaceutical production, several pharmaceutical trade publications reported.
“Over the next year and a half, approximately 350 positions will be created [in Basel], mostly in the areas of development and in innovative biologics manufacturing,” Novartis spokesperson Hannah Miller told Biopharma-Reporter on Friday. “At the same time, we plan to reduce up to 500 positions or move them to other locations – mostly traditional manufacturing, coordination, and development operations roles.”
The cuts include 162 manufacturing positions, 109 workers in development, 117 pharmaceutical management employees, and 105 workers in finance, recruitment, IT, sales, and infrastructure, Genetic Engineering & Biotechnology News reported, noting the Basel workforce reduction represented the Swiss company’s third round of job cuts in under a year.
Novartis told FirstWordPharma.com that it intends to close its production sites in Basel and Schweizerhalle and hinted at wider job cuts ahead as part of the firm’s “ongoing transition to an integrated operating model.”
“The ongoing implementation of this [operating model] results in adjustments to employee numbers worldwide,” the Swiss firm said, FirstWordPharma.com reported.